“Reports Q4 revenue $of $90.1M, consensus $20.63M .”As of December 31… Voyager had approximately $431 million in pro-forma cash on the balance sheet, adjusted for the Novartis agreements and public offering in January 2024. We expect this funding to support the generation of clinical data across multiple programs, with the potential for significant value creation,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “We expect to advance at least four wholly-owned and partnered programs into the clinic by the end of next year. Our most advanced program, the anti-tau antibody VY-TAU01 for Alzheimer’s disease, is expected to reach IND in the first half of this year, and we anticipate generating key tau PET imaging data in the second half of 2026.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
- Voyager Therapeutics reports selection of gene therapy development candidate
- Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
- VYGR Upcoming Earnings Report: What to Expect?
- Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast